Stocktoria
Cronos Group Inc. CRON
Nasdaq · XNAS · stock · Medicinal Chemicals & Botanical Products · website · IPO 2014-05-07
Chart by TradingView
5/9
Piotroski F — financial health
27.23
Altman Z″ — distress risk · safe
—
Dividend payout · no dividend
Financials & ratios (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Financials | |||||
| Revenue | $146.6M | $161.8M | $87.2M | $86.7M | $64.6M |
| Gross profit | $62.8M | $25.2M | $11.9M | $15.4M | -$17.6M |
| Operating income | -$17.4M | -$76.5M | -$84.8M | -$111.4M | -$292.0M |
| Net income | -$9.4M | $41.1M | -$74.0M | -$168.7M | -$396.1M |
| Operating cash flow | $25.9M | $18.8M | -$42.8M | -$88.9M | -$153.6M |
| Free cash flow | $149,000 | $6.4M | -$45.3M | -$92.4M | -$164.8M |
| Total assets | $1.2B | $1.2B | $1.1B | $1.2B | $1.4B |
| Total liabilities | $54.2M | $55.3M | $44.1M | $72.0M | $63.5M |
| Shareholders' equity | $1.1B | $1.1B | $1.1B | $1.1B | $1.3B |
| Ratios | |||||
| Gross margin | 42.8% | 15.6% | 13.7% | 17.8% | -27.3% |
| Operating margin | -11.9% | -47.3% | -97.2% | -128.4% | -452.2% |
| Net margin | -6.4% | 25.4% | -84.8% | -194.5% | -613.5% |
| FCF margin | 0.1% | 4.0% | -52.0% | -106.5% | -255.2% |
| Return on assets | -0.8% | 3.5% | -6.5% | -13.9% | -28.3% |
| Return on equity | -0.9% | 3.7% | -6.7% | -14.8% | -29.7% |
| Current ratio | 19.59 | 18.84 | 22.54 | 14.10 | 19.86 |
| Revenue growth | -9.4% | 85.5% | 0.6% | 34.4% | 38.2% |
Why these scores methodology →
Piotroski F-score: 5/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: 27.23 (safe)
- Working capital / assets 0.748
- Retained earnings / assets 0.374
- EBIT / assets -0.015
- Equity / liabilities 20.19
Sector peers
VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →
Source: SEC EDGAR filings · CIK 0001656472 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.